The fluctuating parkinsonian patient - Clinical and pathophysiological aspects

Canadian Journal of Neurological Sciences

Volumn 30, Issue SUPPL. 1, 2003, Pages

  Blanchet, Pierre J ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

AKATHISIA; AKINESIA; CLINICAL FEATURE; DYSKINESIA; DYSTONIA; HUMAN; HYPOTENSION; MOTOR DYSFUNCTION; MYOCLONUS; ON OFF PHENOMENON; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SOMNOLENCE; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME;

EID: 0037356170     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100003206     Document Type: Review

References (72)

1. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(Suppl 1):S2-S11.
2. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
3. Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996;47:1180-1183.
4. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408-413.
5. Papa SM, Engber TM, Kask AM, Chase TN. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.
6. Merello M, Lees AJ. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:1024-1026.
7. Blanchet PJ, Allard P, Grégoire L, et al. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-193.
8. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
9. Marconi R, Lefebvre-Caparros D, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson's disease. Phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
10. Togasaki DM, Tan L, Protell P, et al. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol 2001;50:254-257.
11. Daras M, Koppel BS, Atos-Radzion E. Cocaine-induced choreoathetoid movements ("crack dancing"). Neurology 1994;44:751-752.
12. de la Fuente-Fernandez R, Pal PK, Vingerhoets FJG, et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 2000;107:49-57.
13. de la Fuente-Fernandez R, Lu J-Q, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
14. 1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord 1996;11:91-94.
15. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002;51:686-693.
16. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150.
17. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
18. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-910.
19. 3H]spiperone binding. Brain Res 1986;379:294-299.
20. Blanchet P, Bédard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Therap 1993;267:275-279.
21. 1 dopamine receptors in striatal neurons in Parkinson's disease. Ann Neurol 1999;46:103-111.
22. 2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 1991;259:409-413.
23. 2 dopamine agonists. Eur J Pharmacol 1989;168:291-298.
24. Engber TM, Susel Z, Kuo S, et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118.
25. Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 1999;155:204-220.
26. 2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Therap 1995;272:854-859.
27. 1 receptor desensitization profile in MPTP-lesioned primates. Eur J Pharmacol 1996;309:13-20.
28. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
29. Blanchet PJ, Calon F, Morissette M, et al. Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model. In: Calne D, Calne SM, (Eds). Parkinson's Disease: Advances in Neurology, vol. 86, Philadelphia, Lippincott Williams & Wilkins, 2001:337-344.
30. 2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. Mol Brain Res 1996;42:149-155.
31. 2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49:717-723.
32. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997;94:3363-3367.
33. 3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett 1996;214:75-78.
34. 2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 1998;13:788-797.
35. A receptors in the striatopallidal complex. Brain Res 1995;680:43-52.
36. B receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments. Exp Neurol 2000;163:191-199.
37. Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Brain 1992;115:809-824.
38. Soghomonian J-J, Pedneault S, Blanchet PJ, et al. L-dopa regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys. Molec Brain Res 1996;39:237-240.
39. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992;76:53-61.
40. Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996;40:355-366.
41. Lang AE, Lozano AM, Montgomery E, et al. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997;337:1036-1042.
42. Volkmann J, Sturm V, Weiss P, et al. Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease. Ann Neurol 1998;44:953-961.
43. Krack P, Pollak P, Limousin P, et al. Inhibition of levodopa effects by internal pallidal stimulation. Mov Disord 1998;13:648-652.
44. Kumar R, Lang AE, Rodriguez-Oroz MC, et al. Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease. Neurology 2000;55(12 suppl 6):S34-S39.
45. Duty S, Brotchie JM. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp Neurol 1997;144:423-432.
46. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42:720-726.
47. Henry B, Fox SH, Crossman AR, Brotchie JM. μ-and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 2001;171:139-146.
48. Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 1996;9:149-158.
49. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S, (Eds). Advances in Neurology, vol 69: Drugs for the Treatment of Parkinson's disease. Philadelphia: Lippincott-Raven, 1996;62:497-501.
50. Brotchie JM. Advances in understanding the neural mechanisms underlying L-dopa-induced dyskinesia. In: Stern GM, (Ed.) Parkinson's Disease. Advances in Neurology, Vol. 80. Philadelphia: Lippincott Williams & Wilkins 1999:71-85.
51. Calon F, Morissette M, Ghribi O, et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:127-138.
52. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996;39:574-578.
53. Blanchet PJ, Konitsiotis S, Whittemore ER, et al. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyltetrahydropyridine monkeys. J Pharmacol Exp Ther 1999;290:1034-1040.
54. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000;54:1589-1595.
55. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
56. Oh JD, Vaughan CL, Chase TN. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 1999;821:433-442.
57. Marin C, Papa SM, Engber TM, et al. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 1996;736:202-205.
58. Doucet J-P, Nakabeppu Y, Bédard PJ, et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of AFosB-like protein(s) in both rodent and primate striatum. Eur J Neurosci 1996;8:365-381.
59. Andersson M, Hilbertson A, Cenci MA. Striatal fosB expression is causally linked with L-dopa-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 2000;6:461-474.
60. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876.
61. Sieradzan KA, Fox SH, Hill M, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001;57:2108-2111.
62. Brotchie JM. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann Neurol 2000;47(Suppl 1):S105-S114.
63. 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001;57:1829-1834.
64. 2a receptor antagonist in MPTP-treated monkeys. Neurology 1999;52:1673-1677.
65. Filion M, Tremblay L, Bédard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547:152-161.
66. Papa SM, Desimone R, Fiorani M, Oldfield EH. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 1999;46:732-738.
67. Albin R, Young A, Penney J. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:336-374.
68. Hutchison WD, Levy R, Dostrovsky JO, et al. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann Neurol 1997;42:767-775.
69. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 2000;47(Suppl 1):S22-S34.
70. Filion M. Physiologic basis of dyskinesia. Ann Neurol 2000;47(Suppl 1):S35-S41.
71. Benabid AL, Benazzouz A, Limousin P, et al. Dyskinesias and the subthalamic nucleus. Ann Neurol 2000;47(Suppl 1):S189-S192.
72. Caparros-Lefebvre D, Blond S, Feltin MP, Pollak P, Benabid AL. Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex. J Neurol Neurosurg Psychiatry 1999;67:308-314.